[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2003042661A3 - Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer - Google Patents

Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer Download PDF

Info

Publication number
WO2003042661A3
WO2003042661A3 PCT/US2002/036810 US0236810W WO03042661A3 WO 2003042661 A3 WO2003042661 A3 WO 2003042661A3 US 0236810 W US0236810 W US 0236810W WO 03042661 A3 WO03042661 A3 WO 03042661A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
cancer
diagnosis
compositions
modulators
Prior art date
Application number
PCT/US2002/036810
Other languages
French (fr)
Other versions
WO2003042661A2 (en
WO2003042661A8 (en
Inventor
Daniel Afar
Natasha Aziz
Wendy M Ginsburg
Kurt C Gish
Richard Glynne
Peter A Hevezi
David H Mack
Richard Murray
Susan R Watson
Keith E Wilson
Albert Zlotnik
Original Assignee
Protein Design Labs Inc
Daniel Afar
Natasha Aziz
Wendy M Ginsburg
Kurt C Gish
Richard Glynne
Peter A Hevezi
David H Mack
Richard Murray
Susan R Watson
Keith E Wilson
Albert Zlotnik
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protein Design Labs Inc, Daniel Afar, Natasha Aziz, Wendy M Ginsburg, Kurt C Gish, Richard Glynne, Peter A Hevezi, David H Mack, Richard Murray, Susan R Watson, Keith E Wilson, Albert Zlotnik filed Critical Protein Design Labs Inc
Priority to AU2002357734A priority Critical patent/AU2002357734A1/en
Priority to EP02792272A priority patent/EP1497454A2/en
Priority to JP2003544445A priority patent/JP2005525789A/en
Priority to CA002467433A priority patent/CA2467433A1/en
Publication of WO2003042661A2 publication Critical patent/WO2003042661A2/en
Publication of WO2003042661A8 publication Critical patent/WO2003042661A8/en
Publication of WO2003042661A3 publication Critical patent/WO2003042661A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Described herein are genes whose expression are up-regulated or down-regulated in specific cancers or other diseases, or are otherwise regulated in disease. Related methods and compositions that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of these selected conditions.
PCT/US2002/036810 2001-11-13 2002-11-13 Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer WO2003042661A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2002357734A AU2002357734A1 (en) 2001-11-13 2002-11-13 Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
EP02792272A EP1497454A2 (en) 2001-11-13 2002-11-13 Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
JP2003544445A JP2005525789A (en) 2001-11-13 2002-11-13 Cancer diagnosis method, cancer modulator screening composition and method
CA002467433A CA2467433A1 (en) 2001-11-13 2002-11-13 Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer

Applications Claiming Priority (37)

Application Number Priority Date Filing Date Title
US35066601P 2001-11-13 2001-11-13
US60/350,666 2001-11-13
US33246401P 2001-11-21 2001-11-21
US60/332,464 2001-11-21
US33439301P 2001-11-29 2001-11-29
US60/334,393 2001-11-29
US33539401P 2001-12-03 2001-12-03
US60/335,394 2001-12-03
US34037601P 2001-12-14 2001-12-14
US60/340,376 2001-12-14
US34721102P 2002-01-08 2002-01-08
US60/347,211 2002-01-08
US34734902P 2002-01-10 2002-01-10
US60/347,349 2002-01-10
US35525702P 2002-02-08 2002-02-08
US35525002P 2002-02-08 2002-02-08
US60/355,250 2002-02-08
US35671402P 2002-02-13 2002-02-13
US60/356,714 2002-02-13
US35907702P 2002-02-20 2002-02-20
US60/359,077 2002-02-20
US36880902P 2002-03-29 2002-03-29
US60/368,809 2002-03-29
US37011002P 2002-04-04 2002-04-04
US60/370,110 2002-04-04
US37224602P 2002-04-12 2002-04-12
US60/372,246 2002-04-12
US38661402P 2002-06-05 2002-06-05
US60/386,614 2002-06-05
US39683902P 2002-07-16 2002-07-16
US60/396,839 2002-07-16
US39784502P 2002-07-22 2002-07-22
US39777502P 2002-07-22 2002-07-22
US60/397,775 2002-07-22
US60/397,845 2002-07-22
US40945002P 2002-09-09 2002-09-09
US60/409,450 2002-09-09

Publications (3)

Publication Number Publication Date
WO2003042661A2 WO2003042661A2 (en) 2003-05-22
WO2003042661A8 WO2003042661A8 (en) 2003-10-16
WO2003042661A3 true WO2003042661A3 (en) 2004-10-28

Family

ID=32097246

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/036810 WO2003042661A2 (en) 2001-11-13 2002-11-13 Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer

Country Status (1)

Country Link
WO (1) WO2003042661A2 (en)

Families Citing this family (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090176722A9 (en) 2000-01-28 2009-07-09 Shiv Srivastava Androgen-regulated PMEPA1 gene and polypeptides
NZ523475A (en) 2000-06-16 2004-09-24 Biogen Inc Renal regulatory elements and methods of use thereof
US20060035237A1 (en) 2002-08-26 2006-02-16 Markowitz Sanford D Methods and compositions for categorizing patients
US7118912B2 (en) * 2002-08-26 2006-10-10 Case Western Reserve University Methods and compositions for categorizing patients
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
ATE382060T1 (en) 2001-06-01 2008-01-15 Biogen Idec Inc MOLECULES AND METHODS FOR INHIBITING THE RELEASE OF KIM-1
JP2005536439A (en) 2001-09-18 2005-12-02 ジェネンテック・インコーポレーテッド Compositions and methods for tumor diagnosis and treatment
CA2478593A1 (en) * 2002-03-04 2003-09-18 Avalon Pharmaceuticals Cancer-linked gene as target for chemotherapy
CA2479732A1 (en) * 2002-03-19 2003-10-02 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP2365004B1 (en) * 2002-06-21 2016-01-06 Johns Hopkins University School of Medicine Membrane associated tumor endothelium markers
CA2492160A1 (en) 2002-07-12 2004-01-22 The Johns Hopkins University Mesothelin vaccines and model systems
US20090110702A1 (en) 2002-07-12 2009-04-30 The Johns Hopkins University Mesothelin Vaccines and Model Systems and Control of Tumors
US9200036B2 (en) 2002-07-12 2015-12-01 The Johns Hopkins University Mesothelin vaccines and model systems
EP1575993A4 (en) * 2002-08-26 2007-07-25 Univ Case Western Reserve Methods for treating patients and identifying therapeutics
EP1546182B1 (en) * 2002-09-11 2011-01-05 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1565482B1 (en) * 2002-10-23 2014-04-30 Ludwig Institute for Cancer Research Ltd. A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same
NZ541404A (en) 2002-12-30 2007-05-31 Biogen Idec Inc Antibody or antigen-binding fragment thereof that binds to KIM-1, or a polypeptide comprising a KIM-I immunoglobulin domain to treat autoimmune diseases
US20040170982A1 (en) * 2003-02-14 2004-09-02 Morris David W. Novel therapeutic targets in cancer
US7094572B2 (en) 2003-03-14 2006-08-22 Bristol-Myers Squibb Polynucleotide encoding a novel human G-protein coupled receptor variant of HM74, HGPRBMY74
JP2006526986A (en) * 2003-06-06 2006-11-30 アストラゼネカ・アクチエボラーグ Diagnosis method for inflammatory bowel disease
EP2289908B1 (en) 2003-07-11 2013-08-07 Evotec International GmbH Use of DG177 secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
US7294704B2 (en) 2003-08-15 2007-11-13 Diadexus, Inc. Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
US20070178458A1 (en) * 2003-09-05 2007-08-02 O'brien Philippa Methods of diagnosis and prognosis of ovarian cancer II
WO2005034732A2 (en) 2003-10-07 2005-04-21 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
ES2605443T3 (en) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
WO2005054864A2 (en) * 2003-11-22 2005-06-16 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with potassium channel, subfamily k, member 1 (kcnk1)
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
EP1584684A1 (en) * 2004-02-20 2005-10-12 Samsung Electronics Co., Ltd. Breast cancer related protein, gene encoding the same, and method of diagnosing breast cancer using the protein and gene
JP2005314397A (en) * 2004-03-31 2005-11-10 Mitsubishi Chemicals Corp Anti-chondromodulin-1-specific antibody and its use
EP2070546A1 (en) * 2004-04-09 2009-06-17 Takeda Pharmaceutical Company Limited Preventives/remedies for cancer
CA2567520A1 (en) 2004-06-01 2005-12-15 Genentech, Inc. Maytansinoid-antibody conjugates
CA2565524A1 (en) * 2004-06-04 2005-12-15 Applied Research Systems Ars Holding N.V. Splice variant of unc5h2
US20060024677A1 (en) * 2004-07-20 2006-02-02 Morris David W Novel therapeutic targets in cancer
WO2006008003A2 (en) * 2004-07-23 2006-01-26 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with vasoactive intestinal peptide receptor 1 (vpac1)
US20090214517A1 (en) * 2004-07-27 2009-08-27 Justin Wong Compositions and methods of use for modulators of nectin 4, semaphorin 4b, igsf9, and kiaa0152 in treating disease
DE102004045705A1 (en) 2004-09-21 2006-04-06 B.R.A.H.M.S Ag Uses of carbamoyl phosphate synthetase 1 (CPS) as a humoral biomarker for the diagnosis of tumors and inflammatory bowel disease
EP3088004B1 (en) 2004-09-23 2018-03-28 Genentech, Inc. Cysteine engineered antibodies and conjugates
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
WO2006053442A1 (en) * 2004-11-22 2006-05-26 Diagnocure Inc. Calml3 a specific and sensitive target for lung cancer diagnosis, prognosis and/or theranosis
JP4993645B2 (en) 2004-12-01 2012-08-08 ジェネンテック， インコーポレイテッド Antibody drug conjugates and methods
WO2006090389A2 (en) * 2005-02-24 2006-08-31 Compugen Ltd. Novel diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof
EP2325306B1 (en) 2005-02-25 2014-02-12 Oncotherapy Science, Inc. Peptide vaccines for lung cancers expressing TTK, URLC10 or KOC1 polypeptides
US8206705B2 (en) 2005-03-02 2012-06-26 Biogen Idec Ma Inc. KIM-1 antibodies for treatment of TH2-mediated conditions
EP1869207A1 (en) * 2005-04-07 2007-12-26 AstraZeneca AB METHOD FOR ASSESSING THE PRESDISPOSITION AND/OR SUSCEPTIBILITY TO COPD BY ANALYSING FGF-BPl
CA2604689A1 (en) * 2005-04-15 2006-10-26 Oncomethylome Sciences, Inc. Methylation markers for diagnosis and treatment of cancers
BRPI0607508B8 (en) * 2005-04-15 2021-07-27 Epigenomics Ag method for detection and/or classification of colorectal or hepatocellular cell proliferative disorders, and use thereof
GB0508863D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Peptide
CN102191320A (en) 2005-05-02 2011-09-21 东丽株式会社 Composition and method for diagnosing esophageal cancer
EP1885751B1 (en) 2005-05-27 2011-11-16 BBS - Bioactive Bone Substitutes Oy Bone morphogenetic protein 6 containing a heparin binding site and osteogenic devices and pharmaceutical products containing thereof
ES2406063T3 (en) 2005-12-08 2013-06-05 Medarex, Inc. Human monoclonal antibodies against the protein Tyrosine Kinase 7 (PTK7) and its use
BRPI0709338A2 (en) 2006-03-21 2011-07-12 Genentech Inc antibody, isolated nucleic acid molecule, cell, compositions, alpha5beta1 protein detection method, antibody use, treatment methods, kit, use of a composition, use of an alpha5beta antagonist, and use of a vegf antagonist
WO2007115213A2 (en) * 2006-03-30 2007-10-11 Epigenomics Ag Methods and nucleic acids for analyses of cellular proliferative disorders
EP2479283B1 (en) * 2006-04-17 2016-06-22 Epigenomics AG Methods and nucleic acids for the detection of colorectal cell proliferative disorders
EP2041319A2 (en) * 2006-07-13 2009-04-01 Epigenomics AG Methods and nucleic acids for analyses of cellular proliferative disorders
EP1932854A1 (en) * 2006-12-15 2008-06-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) Lysosomal associated membrane protein (LAMP) - like polypeptide, ligands to the same, and use of the same in the frame of detection and purification of human plasmacytoid dendritic cells
EP2121738A2 (en) 2007-02-26 2009-11-25 Oxford Genome Sciences (UK) Limited Proteins
WO2008104803A2 (en) 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
ES2546610T3 (en) 2007-07-27 2015-09-25 Immatics Biotechnologies Gmbh New immunotherapy against neuronal and brain tumors
EP3042914B1 (en) 2007-07-27 2018-07-04 immatics biotechnologies GmbH Novel immunogenic epitopes for immunotherapy
AU2012244137B2 (en) * 2007-07-27 2015-06-11 Immatics Biotechnologies Gmbh Novel immunotherapy against neuronal and brain tumours
AU2008296927C1 (en) 2007-09-06 2015-08-13 Case Western Reserve University Methods for diagnosing and treating cancers
PE20091029A1 (en) 2007-09-26 2009-08-19 Genentech Inc ANTI-ALPHA ANTIBODIES 5 BETA 1
NZ587506A (en) 2008-01-25 2012-09-28 Univ Aarhus Selective exosite inhibition of papp-a activity against igfbp-4
DK2257301T3 (en) 2008-03-03 2014-04-28 Univ Miami Immunotherapy based on allogeneic cancer cells.
DK2119726T5 (en) * 2008-05-14 2018-03-26 Immatics Biotechnologies Gmbh Novel and powerful MHC class II peptides derived from survivin and neurocan
CN103540657A (en) 2008-05-21 2014-01-29 东丽株式会社 Composition and method for determination of esophageal cancer
NZ589806A (en) * 2008-05-30 2012-08-31 Curis Inc Variant hedgehog-interacting protein (hhip1) and methods and uses thereof
CA2727915C (en) 2008-07-15 2016-04-26 Genentech, Inc. Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
US9290556B2 (en) 2008-09-29 2016-03-22 The Trustees Of The University Of Pennsylvania Tumor vascular marker-targeted vaccines
EP2411411B1 (en) 2009-03-25 2016-08-31 F.Hoffmann-La Roche Ag Novel anti-alpha5beta1 antibodies and uses thereof
AU2010268690B2 (en) 2009-07-03 2011-11-10 Avipep Pty Ltd Immuno-conjugates and methods for producing them
EP2475391B1 (en) 2009-09-09 2018-09-12 Centrose, LLC Extracellular targeted drug conjugates
WO2011075786A1 (en) 2009-12-23 2011-06-30 Avipep Pty Ltd Immuno-conjugates and methods for producing them 2
CN102933236B (en) 2010-04-15 2014-10-08 斯皮罗根有限公司 Pyrrolobenzodiazepines and conjugates thereof
CN103068406B (en) 2010-06-08 2017-06-30 基因泰克公司 Cysteine engineered antibody and conjugate
KR102295534B1 (en) 2010-09-29 2021-08-30 어젠시스 인코포레이티드 Antibody drug conjugates (adc) that bind to 191p4d12 proteins
CN103313990B (en) 2010-11-17 2016-07-20 基因泰克公司 Alanyl maytansinol antibody coupling matter
EP3103810A3 (en) 2011-04-21 2017-03-08 Garvan Institute of Medical Research Modified variable domain molecules and methods for producing and using them
CN103608684B (en) 2011-05-12 2016-05-04 基因泰克公司 Utilize framework signature peptide to detect the multiple reaction monitoring LC-MS/MS method of the therapeutic antibodies in animal sample
WO2013045464A1 (en) * 2011-09-26 2013-04-04 Roche Diagnostics Gmbh Cdna biomarkers in whole blood for colorectal cancer assessment
HUE025661T2 (en) 2011-10-14 2016-04-28 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
EP2891663B8 (en) 2012-08-31 2018-04-04 Vasculead Inc. Psf1-derived peptide
KR101645905B1 (en) 2012-10-12 2016-08-04 스피로즌 살 Pyrrolobenzodiazepines and conjugates thereof
NZ707490A (en) 2012-10-12 2018-09-28 Adc Therapeutics Sa Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
US10695433B2 (en) 2012-10-12 2020-06-30 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
KR101995620B1 (en) 2012-10-12 2019-07-03 에이디씨 테라퓨틱스 에스에이 Pyrrolobenzodiazepine-antibody conjugates
RS57694B1 (en) 2012-10-12 2018-11-30 Adc Therapeutics Sa Pyrrolobenzodiazepine - anti-psma antibody conjugates
MX364329B (en) 2012-10-12 2019-04-23 Medimmune Ltd Pyrrolobenzodiazepine-antibody conjugates.
ES2680153T3 (en) 2012-10-12 2018-09-04 Adc Therapeutics Sa Anti-PSMA-pyrrolobenzodiazepine antibody conjugates
WO2014096365A1 (en) 2012-12-21 2014-06-26 Spirogen Sàrl Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
EP2935268B2 (en) 2012-12-21 2021-02-17 MedImmune Limited Pyrrolobenzodiazepines and conjugates thereof
CA2904044C (en) 2013-03-13 2020-03-31 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
ES2687439T3 (en) 2013-03-13 2018-10-25 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
EP2968596B1 (en) 2013-03-13 2019-03-06 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
CA2918139A1 (en) 2013-08-12 2015-02-19 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
EP3054985B1 (en) 2013-10-11 2018-12-26 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
WO2015052535A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
PE20160561A1 (en) 2013-10-11 2016-06-03 Oxford Biotherapeutics Ltd CONJUGATED ANTIBODIES AGAINST LY75 FOR THE TREATMENT OF CANCER
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
KR20170042495A (en) 2013-12-16 2017-04-19 제넨테크, 인크. Peptidomimetic compounds and antibody-drug conjugates thereof
WO2015095223A2 (en) 2013-12-16 2015-06-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
WO2015095212A1 (en) 2013-12-16 2015-06-25 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
GB201408100D0 (en) * 2014-05-07 2014-06-18 Sec Dep For Health The Detection method
CN106687141A (en) 2014-09-10 2017-05-17 麦迪穆有限责任公司 Pyrrolobenzodiazepines and conjugates thereof
SG11201701128YA (en) 2014-09-12 2017-03-30 Genentech Inc Cysteine engineered antibodies and conjugates
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
EP3191134B1 (en) 2014-09-12 2019-11-20 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
MA40575A (en) 2014-09-17 2016-03-24 Genentech Inc Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
US10780096B2 (en) 2014-11-25 2020-09-22 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
CN107206101B (en) 2014-12-03 2021-06-25 基因泰克公司 Quaternary ammonium compounds and antibody-drug conjugates thereof
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
MA43345A (en) 2015-10-02 2018-08-08 Hoffmann La Roche PYRROLOBENZODIAZEPINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
MA43354A (en) 2015-10-16 2018-08-22 Genentech Inc CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE
MA45326A (en) 2015-10-20 2018-08-29 Genentech Inc CALICHEAMICIN-ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
WO2017165734A1 (en) 2016-03-25 2017-09-28 Genentech, Inc. Multiplexed total antibody and antibody-conjugated drug quantification assay
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
EP3458101B1 (en) 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Protac antibody conjugates and methods of use
JP7022080B2 (en) 2016-05-27 2022-02-17 ジェネンテック， インコーポレイテッド Biochemical analytical methods for the characterization of site-specific antibody-drug conjugates
EP3464280B1 (en) 2016-06-06 2021-10-06 F. Hoffmann-La Roche AG Silvestrol antibody-drug conjugates and methods of use
JP7093767B2 (en) 2016-08-11 2022-06-30 ジェネンテック， インコーポレイテッド Pyrrolobenzodiazepine prodrug and its antibody conjugate
JP7050770B2 (en) 2016-10-05 2022-04-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Method for preparing antibody drug conjugate
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
ES2871001T3 (en) 2017-02-08 2021-10-28 Adc Therapeutics Sa Conjugates of pyrrolobenzodiazepines and antibodies
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
JP2020517609A (en) 2017-04-18 2020-06-18 メディミューン リミテッド Pyrrolobenzodiazepine complex
BR112019021880A2 (en) 2017-04-20 2020-06-02 Adc Therapeutics Sa COMBINATION THERAPY WITH ANTI-AXL-DRUG ANTIBODY CONJUGATE
UA127900C2 (en) 2017-06-14 2024-02-07 Ейдісі Терапьютікс Са Dosage regimes for the administration of an anti-cd19 adc
RS62928B1 (en) 2017-08-18 2022-03-31 Medimmune Ltd Pyrrolobenzodiazepine conjugates
MX2020003089A (en) 2017-09-20 2020-10-15 Ph Pharma Co Ltd Thailanstatin analogs.
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
CA3115110A1 (en) 2018-10-24 2020-04-30 F. Hoffmann-La Roche Ag Conjugated chemical inducers of degradation and methods of use
EP3894427A1 (en) 2018-12-10 2021-10-20 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
CN112083168A (en) * 2019-06-14 2020-12-15 复旦大学附属华山医院 Polypeptide fragment diagnosis model and application thereof in predicting medulloblastoma metastasis risk
CN110819714B (en) * 2019-11-22 2023-01-10 南方医科大学深圳医院 Cancer suppressor gene and application thereof
CN114350640B (en) * 2019-12-13 2023-09-08 中国科学院天津工业生物技术研究所 Construction of recombinant bacterium for expressing chitinase and screening of high-enzyme activity mutant
CN111748623B (en) * 2020-06-08 2022-11-04 郑州大学第一附属医院 Predictive marker and kit for recurrence of liver cancer patient
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
AR128330A1 (en) 2022-01-26 2024-04-17 Genentech Inc CHEMICAL DEGRADATION INDUCERS CONJUGATED WITH ANTIBODY AND METHODS OF THESE
AR128331A1 (en) 2022-01-26 2024-04-17 Genentech Inc CHEMICAL DEGRADATION INDUCTORS CONJUGATED WITH ANTIBODIES AND METHODS OF THESE
CN114966062B (en) * 2022-07-29 2022-09-30 北京大学第三医院（北京大学第三临床医学院） Molecular marker for predicting anti-MDA 5 antibody positive dermatomyositis combined with interstitial lung disease and application thereof
WO2024138128A2 (en) 2022-12-23 2024-06-27 Genentech, Inc. Cereblon degrader conjugates, and uses thereof
WO2024220546A2 (en) 2023-04-17 2024-10-24 Peak Bio, Inc. Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KIM J.Y. ET AL: "Human cystine/glutamate transporter: cDNA cloning and upregulation by oxidative stress in glioma cells", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1512, June 2001 (2001-06-01), pages 335 - 344, XP004245520 *
SATO H. ET AL: "Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins", J. BIOL. CHEM., vol. 274, no. 17, 23 April 1999 (1999-04-23), pages 11455 - 11458, XP002941607 *

Also Published As

Publication number Publication date
WO2003042661A2 (en) 2003-05-22
WO2003042661A8 (en) 2003-10-16

Similar Documents

Publication Publication Date Title
WO2003042661A3 (en) Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
WO2002059377A3 (en) Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
WO2003025138A3 (en) Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
WO2004073657A3 (en) Methods of diagnosis of cancer and other diseases, composition and methods of screening for modulators of cancer and other diseases
WO2003003906A3 (en) Diagnostic and screening methods for bladder cancer
WO2002102235A3 (en) Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
WO2004048938A3 (en) Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
WO2002030268A3 (en) Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
WO2004063355A3 (en) Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer
WO2005047534A3 (en) Methods and compositions for the response prediction of malig-nant neoplasia to treatment
WO2004065583A3 (en) Gene expression markers for breast cancer prognosis
WO2004008147A3 (en) Diagnosis and prevention of cancer cell invasion
HK1203568A1 (en) Gene expression profiling in biopsied tumor tissues
EP1365034A3 (en) Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasia
TNSN05300A1 (en) Treatment with anti-vegf antibodies
WO2003087831A3 (en) Proteins involved in breast cancer
DE60028970D1 (en) AT HER2 BINDING PEPTIDE COMPOUNDS
AU2003300368A1 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
AU2002251366A1 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
AU2002338852A1 (en) Genes and proteins for prevention, prediction, prognosis and therapy of cardiovascular disease
WO2003079982A3 (en) Gene amplification in cancer
WO2004046332A3 (en) Amplified genes involved in cancer
WO2001071357A3 (en) Diagnosis and treatment of breast cancer
AU6583700A (en) Proteins, genes and their use for diagnosis and treatment of breast cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 21/2003 UNDER (30) REPLACE "NOT FURNISHED" BY "60/355,250"

Free format text: IN PCT GAZETTE 21/2003 UNDER (30) REPLACE "NOT FURNISHED" BY "60/355,250"

WWE Wipo information: entry into national phase

Ref document number: 2002792272

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2467433

Country of ref document: CA

Ref document number: 2003544445

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2002792272

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002792272

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)